Cancer‐associated fibroblast‐derived exosomal microRNA‐24‐3p enhances colon cancer cell resistance to MTX by down‐regulating CDX2/HEPH axis

MicroRNA‐24‐3p (miR‐24‐3p) has been implicated as a key promoter of chemotherapy resistance in numerous cancers. Meanwhile, cancer‐associated fibroblasts (CAFs) can secret exosomes to transfer miRNAs, which mediate tumour development. However, little is known regarding the molecular mechanism of CAF‐derived exosomal miR‐24‐3p in colon cancer (CC). Hence, this study intended to characterize the functional relevance of CAF‐derived exosomal miR‐24‐3p in CC cell resistance to methotrexate (MTX). We identified differentially expressed HEPH, CDX2 and miR‐24‐3p in CC through bioinformatics analyses, and validated their expression in CC tissues and cells. The relationship among HEPH, CDX2 and miR‐24‐3p was verified using ChIP and dual‐luciferase reporter gene assays. Exosomes were isolated from miR‐24‐3p inhibitor–treated CAFs (CAFs‐exo/miR‐24‐3p inhibitor), which were used in combination with gain‐of‐function and loss‐of‐function experiments and MTX treatment. CCK‐8, flow cytometry and colony formation assays were conducted to determine cell viability, apoptosis and colony formation, respectively. Based on the findings, CC tissues and cells presented with high expression of miR‐24‐3p and low expression of HEPH and CDX2. CDX2 was a target gene of miR‐24‐3p and could up‐regulate HEPH. Under MTX treatment, overexpressed CDX2 or HEPH and down‐regulated miR‐24‐3p reduced cell viability and colony formation and elevated cell apoptosis. Furthermore, miR‐24‐3p was transferred into CC cells via CAF‐derived exosomes. CAF‐derived exosomal miR‐24‐3p inhibitor diminished cell viability and colony formation and increased cell apoptosis in vitro and inhibited tumour growth in vivo under MTX treatment. Altogether, CAF‐derived exosomal miR‐24‐3p accelerated resistance of CC cells to MTX by down‐regulating CDX2/HEPH axis.

[1]  N. Wu,et al.  Dysregulation of the miR-325-3p/DPAGT1 axis supports HBV-positive HCC chemoresistance. , 2019, Biochemical and biophysical research communications.

[2]  Wenchuan Wu,et al.  Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer. , 2019, Experimental cell research.

[3]  Peng Wang,et al.  Decreased expression of mitochondrial miR-5787 contributes to chemoresistance by reprogramming glucose metabolism and inhibiting MT-CO3 translation , 2019, Theranostics.

[4]  Xu Han,et al.  Overexpression miR‐24‐3p repressed Bim expression to confer tamoxifen resistance in breast cancer , 2019, Journal of cellular biochemistry.

[5]  Yan Ding,et al.  CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer , 2019, Molecular Cancer.

[6]  Zhengfei Zhu,et al.  Role of Exosomes in Crosstalk Between Cancer-Associated Fibroblasts and Cancer Cells , 2019, Front. Oncol..

[7]  Caitlyn A. Miller,et al.  SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer , 2019, Modern Pathology.

[8]  Hong Wei,et al.  Down-regulated expression of LINC00518 prevents epithelial cell growth and metastasis in breast cancer through the inhibition of CDX2 methylation and the Wnt signaling pathway. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[9]  B. Nabet,et al.  Exosomes in the tumor microenvironment as mediators of cancer therapy resistance , 2019, Molecular Cancer.

[10]  A. Carrato,et al.  Novel Molecular Characterization of Colorectal Primary Tumors Based on miRNAs , 2019, Cancers.

[11]  H. Xiong,et al.  Omeprazole prevents CDX2 and SOX9 expression by inhibiting hedgehog signaling in Barrett's esophagus cells. , 2019, Clinical science.

[12]  Xu Wang,et al.  Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5 , 2019, Genome Biology.

[13]  Dong Liu,et al.  CDX2 inhibits the proliferation and tumor formation of colon cancer cells by suppressing Wnt/β-catenin signaling via transactivation of GSK-3β and Axin2 expression , 2019, Cell Death & Disease.

[14]  Massimo Libra,et al.  Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium , 2018, Front. Pharmacol..

[15]  Hanchen Xu,et al.  Drug resistance and new therapies in colorectal cancer , 2018, World journal of gastroenterology.

[16]  L. Ding,et al.  Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19 , 2018, Theranostics.

[17]  Alireza Khodadadi-Jamayran,et al.  Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process , 2018, Oncotarget.

[18]  Y. Liu,et al.  miR‐24‐3p promotes cell migration and proliferation in lung cancer by targeting SOX7 , 2018, Journal of cellular biochemistry.

[19]  K. Veselkov,et al.  Exosomal microRNAs derived from colorectal cancer-associated fibroblasts: role in driving cancer progression , 2017, Aging.

[20]  Weisha Liu,et al.  A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells. , 2017, Molecular bioSystems.

[21]  L. Ye,et al.  miR-19b-3p promotes colon cancer proliferation and oxaliplatin-based chemoresistance by targeting SMAD4: validation by bioinformatics and experimental analyses , 2017, Journal of experimental & clinical cancer research : CR.

[22]  Chen Huang,et al.  miR‐338‐3p confers 5‐fluorouracil resistance in p53 mutant colon cancer cells by targeting the mammalian target of rapamycin , 2017, Experimental cell research.

[23]  Fengming Yang,et al.  Exosomal miRNAs and miRNA dysregulation in cancer-associated fibroblasts , 2017, Molecular Cancer.

[24]  J. Boratýnski,et al.  Methotrexate and epirubicin conjugates as potential antitumor drugs. , 2017, Postepy higieny i medycyny doswiadczalnej.

[25]  E. Sikora,et al.  Oxidative stress and inhibition of nitric oxide generation underlie methotrexate-induced senescence in human colon cancer cells , 2017, Mechanisms of Ageing and Development.

[26]  Xiaolong Wang,et al.  Targeted CDX2 expression inhibits aggressive phenotypes of colon cancer cells in vitro and in vivo , 2017, International journal of oncology.

[27]  G. Kollias,et al.  Mesenchymal Cells in Colon Cancer. , 2017, Gastroenterology.

[28]  Philippe Lavalle,et al.  The tumor suppressor CDX2 opposes pro-metastatic biomechanical modifications of colon cancer cells through organization of the actin cytoskeleton. , 2017, Cancer letters.

[29]  Zhaohui Jia,et al.  miR-24-3p regulates bladder cancer cell proliferation, migration, invasion and autophagy by targeting DEDD. , 2017, Oncology reports.

[30]  S. Freels,et al.  Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer , 2016, Cancer.

[31]  R. Müller,et al.  Shipping Drug Resistance: Extracellular Vesicles in Ovarian Cancer. , 2016, Trends in molecular medicine.

[32]  Xiaofeng Sun,et al.  miRNA-24-3p promotes cell proliferation and regulates chemosensitivity in head and neck squamous cell carcinoma by targeting CHD5. , 2016, Future oncology.

[33]  Raghu Kalluri,et al.  The biology and function of exosomes in cancer. , 2016, The Journal of clinical investigation.

[34]  A. Concheiro,et al.  Microemulsions for Colorectal Cancer Treatments. General Considerations and Formulation of Methotrexate. , 2016, Mini reviews in medicinal chemistry.

[35]  W. Dong,et al.  MicroRNA‐494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD , 2015, IUBMB life.

[36]  Long-Bang Chen,et al.  Mir-24-3p downregulation contributes to VP16–DDP resistance in small-cell lung cancer by targeting ATG4A , 2014, Oncotarget.

[37]  S. Ichwan,et al.  Nutraceuticals as potential therapeutic agents for colon cancer: a review , 2014, Acta pharmaceutica Sinica. B.

[38]  Masahito Katsuki,et al.  Thyroid hormone negatively regulates CDX2 and SOAT2 mRNA expression via induction of miRNA-181d in hepatic cells. , 2013, Biochemical and biophysical research communications.

[39]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[40]  Y. Yuasa,et al.  MiR‐9 downregulates CDX2 expression in gastric cancer cells , 2011, International journal of cancer.

[41]  Wei Wang,et al.  Effects of Homeodomain Protein CDX2 Expression on the Proliferation and Migration of Lovo Colon Cancer Cells , 2011, Pathology & Oncology Research.

[42]  Matthew A. Titmus,et al.  Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells , 2010, Molecular Cancer.

[43]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[44]  P. Micke,et al.  Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy , 2005, Expert opinion on therapeutic targets.

[45]  R. Kuick,et al.  CDX2-regulated expression of iron transport protein hephaestin in intestinal and colonic epithelium. , 2005, Gastroenterology.

[46]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .